Immunovant, Inc. IMVT United States — United States – Federal
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CurrentFederalTaxExpenseBenefit.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s united states — united states – federal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s united states — united states – federal?
- Immunovant, Inc. (IMVT) reported united states — united states – federal of $0 in Q1 2026.
- How has Immunovant, Inc.'s united states — united states – federal changed year-over-year?
- Immunovant, Inc.'s united states — united states – federal decreased by 100.0% year-over-year, from $220K to $0.
- What is the long-term trend for Immunovant, Inc.'s united states — united states – federal?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s united states — united states – federal has grown at a -100.0% compound annual growth rate (CAGR), from -$85K to $0.
- What does united states — united states – federal mean?
- Refers to the portion of income tax expense or benefit attributable to the United States federal government for the domestic segment. This reflects the tax obligations or credits incurred at the national level based on domestic earnings. It is essential for understanding the impact of federal tax policy on the company's domestic financial results.